616450
TGF-β1, Human Platelets
Synonym(s):
hTGF-β1, Transforming Growth Factor-β1
Assay
≥97% (SDS-PAGE)
Quality Level
form
lyophilized
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
avoid repeated freeze/thaw cycles
impurities
≤1 EU/μg Endotoxin (EU/ug of TGF-β1)
shipped in
ambient
storage temp.
−20°C
General description
Native transforming growth factor-β1 from human platelets. Promotes apoptosis in resting human B lymphocytes, glioma cells, and trigeminal neurinomal cells.
Native transforming growth factor-β1 from human platelets. Promotes apoptosis in resting human B lymphocytes, glioma cells, and trigerminal neurinomal cells.
Biochem/physiol Actions
ED₅₀ = 40-10 pg/ml as measured by the inhibition of IL-4-dependant proliferation of mouse HT-2 cells using resazurin dye as an indicator of cell proliferation.
Physical form
Lyophilized from a sterile-filtered solution of 50 µg BSA/µg TGF-β1, 35% acetonitrile, 0.1% TFA.
Preparation Note
Following reconstitution, store in the refrigerator (4°C) for short-term storage or freeze (-20°C) for long-term storage. Avoid freeze/thaw cycles of solutions. Stock solutions are stable for up to 1 months at 4°C or up to 3 months at -20°C..
Prepared from blood that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Reconstitute to a concentration ≥10 µg/ml in sterile 4 mM HCl containing ≥0.1% HSA or BSA.
Other Notes
Lomo, J., et al. 1995. J. Immunol.154, 1634.
Marushige, K. and Marushige, Y. 1995. Anticancer Res.14, 2419.
Bermundez, L.E. 1993. J. Immunol.150, 1838.
Hamilton, J.A., et al. 1993. J. Immunol.150, 1496.
Reilly, J.T., et al. 1993. Br. J. Haematol.83, 58.
Sporn, M.B. and Roberts, A.B. 1993. Growth Factors8, 1.
Marushige, K. and Marushige, Y. 1995. Anticancer Res.14, 2419.
Bermundez, L.E. 1993. J. Immunol.150, 1838.
Hamilton, J.A., et al. 1993. J. Immunol.150, 1496.
Reilly, J.T., et al. 1993. Br. J. Haematol.83, 58.
Sporn, M.B. and Roberts, A.B. 1993. Growth Factors8, 1.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Regulatory Information
新产品
This item has
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Hui Zhao et al.
Molecular cancer therapeutics, 11(2), 503-513 (2011-12-14)
A growing body of data indicates that inhibiting the type 1 insulin-like growth factor receptor (IGF-1R) might be an effective treatment strategy for hepatocellular carcinoma (HCC). OSI-906 is a dual IGF-1R/IR kinase inhibitor currently in phase II clinical development for
Uyen Q Le et al.
Scientific reports, 12(1), 19504-19504 (2022-11-15)
Triple negative breast cancer (TNBC) is a disease of poor prognosis, with the majority classified as the basal-like subtype associated with epithelial-mesenchymal transition and metastasis. Because basal breast cancers originate from proliferative luminal progenitor-like cells upon dysregulation of proper luminal
Gretchen M Argast et al.
Cells, tissues, organs, 193(1-2), 114-132 (2010-11-03)
Epithelial to mesenchymal transition (EMT) plays a dual role in tumor progression. It enhances metastasis of tumor cells by increasing invasive capacity and promoting survival, and it decreases tumor cell sensitivity to epithelial cell-targeting agents such as epithelial growth factor
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service